Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AEB071 b.i.d./ everolimus · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| cyclosporine (reduced exposure) / everolimus | ACTIVE_COMPARATOR | - |
| AEB071 300 mg b.i.d. / everolimus | EXPERIMENTAL | - |
| AEB071 200 mg b.i.d. / everolimus | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| cyclosporine (reduced exposure) / everolimus | DRUG | twice daily |
| AEB071 300 mg b.i.d. / everolimus | DRUG | twice daily |
| AEB071 200 mg b.i.d. / everolimus | DRUG | twice daily |
Inclusion criteria: * Patient has been maintained on study drug for 12 months in the core study Exclusion criteria: * Not applicable * Other protocol-defined inclusion/exclusion criteria may apply
AEB071 b.i.d./ everolimus is an investigational small molecule being studied for use in kidney transplantation. It is being evaluated as a treatment for de novo renal transplant recipients, meaning patients who have recently received a kidney transplant. The drug is currently in Phase 2 clinical development.
AEB071 b.i.d./ everolimus is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in kidney transplant patients.
AEB071 b.i.d./ everolimus is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The drug is being evaluated for use in kidney transplantation, specifically in de novo renal transplant recipients.
AEB071 b.i.d./ everolimus has been studied in a Phase 2 clinical trial with the identifier NCT00820911. This trial, titled 'Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients,' enrolled 175 participants and has been completed. The trial was conducted across multiple countries including Argentina, Australia, Austria, Belgium, Brazil, Colombia, Czechia, France, Germany, Italy, Netherlands, Norway, Singapore, Slovakia, Spain, Switzerland, and Taiwan.
AEB071 b.i.d./ everolimus is not the same as cyclosporine. In the clinical trial NCT00820911, AEB071 was compared against cyclosporine in de novo renal transplant recipients. The trial was active-controlled, meaning AEB071 was tested against an active comparator, cyclosporine, to evaluate its efficacy and safety.